Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BRIUMVI vs BENLYSTA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
BRIUMVI (ublituximab) is a recombinant, chimeric, humanized monoclonal antibody that binds to CD20, a transmembrane antigen expressed on pre-B and mature B lymphocytes. Binding to CD20 results in antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), leading to B-cell depletion.
Belimumab is a human Ig G1λ monoclonal antibody that binds to soluble B-lymphocyte stimulator (BLy S, also known as BAFF), inhibiting its activity. BLy S is a cytokine that promotes B-cell survival and differentiation. By binding BLy S, belimumab reduces the survival of B cells, including autoreactive B cells, and decreases the production of autoantibodies.
Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults
Systemic lupus erythematosus (SLE) in patients with active, autoantibody-positive disease receiving standard therapy,Lupus nephritis (in combination with standard therapy)
BRIUMVI (ublituximab) 150 mg administered as an intravenous infusion over 4 hours once weekly for 3 weeks, then 150 mg once every 6 months thereafter.
10 mg/kg IV over 1 hour at 2-week intervals for the first 3 doses, then 10 mg/kg IV every 4 weeks; or 200 mg SC once weekly (after loading dose of 200 mg SC weekly for 4 doses for SC initiation).
Terminal elimination half-life is approximately 19-20 days (range 11-30 days) in patients with relapsing multiple sclerosis. The long half-life supports every-6-month dosing.
Terminal half-life approximately 18.6 days (range 13–31 days) in patients with SLE, supporting monthly intravenous dosing.
Ublituximab is a monoclonal antibody catabolized into small peptides and amino acids via general protein degradation pathways; no specific metabolic enzymes are involved.
Belimumab is a monoclonal antibody and is not metabolized by cytochrome P450 enzymes; clearance is thought to occur via proteolytic degradation.
BRIUMVI (ublituximab) is a monoclonal antibody. Elimination occurs via intracellular catabolism and is not excreted renally or fecally in significant amounts. No specific excretion data available.
Not extensively characterized; expected to be degraded into small peptides and amino acids via general protein catabolism. Renal and fecal elimination are minor pathways.
Not extensively bound to plasma proteins (expected low binding for monoclonal antibodies); specific % not reported.
Approximately 65–70% bound to plasma proteins, primarily immunoglobulins and albumin.
Approximately 3.5 L (not weight-based; ~0.05 L/kg for a 70 kg patient). Small Vd consistent with limited extravascular distribution of monoclonal antibodies.
Vd ~ 0.19 L/kg (approximately 13.5 L for a 70 kg adult), indicating limited distribution primarily to the vascular space.
100% (intravenous administration only; not administered via other routes).
SC: ~82% relative to IV; IV: 100%.
No dose adjustment is recommended for patients with mild to moderate renal impairment. Not studied in severe renal impairment (GFR <30 m L/min) or end-stage renal disease.
No dose adjustment required for mild to moderate renal impairment (Cr Cl >=30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or ESRD. Use caution and consider benefit-risk.
No dose adjustment recommended for mild hepatic impairment (Child-Pugh A). Not studied in moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment.
No dedicated studies; however, belimumab is not metabolized by the liver. No dose adjustment recommended based on Child-Pugh class.
Safety and effectiveness in pediatric patients (age <18 years) have not been established. No recommended dosing.
In pediatric patients (>=5 years): IV: 10 mg/kg IV at 2-week intervals for first 3 doses, then 10 mg/kg IV every 4 weeks. SC: 200 mg SC once weekly (after loading dose of 200 mg SC weekly for 4 doses). Not approved for children <5 years.
No specific dose adjustment is recommended. Clinical studies did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients.
No specific dose adjustment; select with caution due to greater frequency of decreased hepatic, renal, or cardiac function, and concomitant disease or drug therapy. Monitor for infections and adverse reactions.
None
No FDA black box warning.
Infusion reactions (may require premedication and monitoring),Increased risk of infections (including serious and life-threatening infections),Progressive multifocal leukoencephalopathy (PML) in patients treated with anti-CD20 therapies,Hepatitis B reactivation (perform HBV screening before initiation),Immunoglobulin levels reduction requiring monitoring,Increased risk of malignancies (breast cancer observed in clinical trials)
Hypersensitivity reactions including anaphylaxis,Infusion reactions,Increased risk of serious infections, including tuberculosis and opportunistic infections,Malignancy risk (potential),Hypogammaglobulinemia,Depression and suicidality
Active hepatitis B infection,Severe, active infections (until resolved)
None known; caution in patients with severe active infections.
No known food interactions. Grapefruit and other CYP450 modulators are not expected to affect ublituximab as it is a monoclonal antibody cleared via catabolism.
No known food interactions. May be taken without regard to meals.
BRIUMVI (ublituximab) is a monoclonal antibody, and Ig G antibodies are known to cross the placenta increasingly after the first trimester, with highest transfer in the third trimester. Based on its mechanism of action (CD20-mediated B-cell depletion), there is a potential risk of transient peripheral B-cell depletion in the fetus. Animal studies have not been conducted with ublituximab; however, other anti-CD20 antibodies have shown no teratogenicity but can cause neonatal B-cell depletion. The drug should be avoided during pregnancy unless the benefit justifies the potential risk.
First trimester: Based on animal studies, belimumab may cause fetal harm due to known immunomodulatory effects; limited human data. Second trimester: Potential for fetal B-cell depletion as Ig G crosses placenta after 13 weeks gestation. Third trimester: Ig G actively transported across placenta; risk of neonatal immunosuppression (e.g., prolonged B-cell depletion, increased infection risk).
It is unknown whether ublituximab is excreted in human milk. Monoclonal antibodies are generally present in breast milk in low amounts, but absorption by the infant is limited due to gastrointestinal degradation. Since ublituximab can cause B-cell depletion, a risk to the breastfed infant cannot be excluded. The M/P ratio is not known.
No human data on belimumab in breast milk. Belimumab is a large monoclonal antibody likely present in milk at low concentrations. M/P ratio unknown. Developmental benefits of breastfeeding should be weighed against potential infant exposure and risk of immunosuppression.
No specific dose adjustments are recommended during pregnancy due to lack of pharmacokinetic data. However, pregnancy can alter clearance and volume of distribution for monoclonal antibodies, potentially affecting exposure. Current guidelines do not specify dose modifications for ublituximab in pregnancy; clinical judgment is advised.
No dose adjustment recommended based on pregnancy pharmacokinetic changes. However, caution advised due to limited data. Dose may need adjustment if concomitant immunosuppressants used.
Premedicate with corticosteroids, antihistamines, and acetaminophen to reduce infusion reactions. Monitor for hypersensitivity reactions, especially during first infusion. Screen for hepatitis B and tuberculosis before initiation. Avoid live vaccines during treatment. Consider JCV antibody status due to risk of progressive multifocal leukoencephalopathy (PML) with anti-CD20 therapies.
BENLYSTA (belimumab) is a BLy S-specific inhibitor for adjunctive therapy in active systemic lupus erythematosus (SLE). Monitor for hypersensitivity reactions during infusion. Do not administer with live vaccines. Contraindicated in severe active lupus nephritis or severe active CNS lupus. Renal function monitoring required due to potential for progressive multifocal leukoencephalopathy (PML) risk.
You must take premedications before each infusion to lower the risk of allergic reactions.,Report any symptoms like fever, chills, rash, or difficulty breathing during or after infusion.,Inform your doctor if you have a history of hepatitis B, tuberculosis, or any infections.,Do not receive live vaccines while on this medication and for a period after stopping.,This drug may increase your risk of infections; contact your doctor if you develop signs of infection.,You will need regular blood tests to monitor for side effects.
Report any signs of allergic reaction during or after infusion immediately.,Avoid live vaccines during treatment and for at least 30 days after stopping.,Inform doctor of any new or worsening neurological symptoms.,Use effective contraception during therapy and for 4 months after last dose.,Do not stop or change dose without consulting your rheumatologist.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BRIUMVI vs BENLYSTA, answered by our medical review team.
BRIUMVI is a Monoclonal Antibody that works by BRIUMVI (ublituximab) is a recombinant, chimeric, humanized monoclonal antibody that binds to CD20, a transmembrane antigen expressed on pre-B and mature B lymphocytes. Binding to CD20 results in antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), leading to B-cell depletion.. BENLYSTA is a Monoclonal Antibody that works by Belimumab is a human Ig G1λ monoclonal antibody that binds to soluble B-lymphocyte stimulator (BLy S, also known as BAFF), inhibiting its activity. BLy S is a cytokine that promotes B-cell survival and differentiation. By binding BLy S, belimumab reduces the survival of B cells, including autoreactive B cells, and decreases the production of autoantibodies.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BRIUMVI and BENLYSTA depend on the specific clinical indication. These are both Monoclonal Antibody agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BRIUMVI is: BRIUMVI (ublituximab) 150 mg administered as an intravenous infusion over 4 hours once weekly for 3 weeks, then 150 mg once every 6 months thereafter.. The standard adult dose of BENLYSTA is: 10 mg/kg IV over 1 hour at 2-week intervals for the first 3 doses, then 10 mg/kg IV every 4 weeks; or 200 mg SC once weekly (after loading dose of 200 mg SC weekly for 4 doses for SC initiation).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BRIUMVI and BENLYSTA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BRIUMVI is classified as Category C. BRIUMVI (ublituximab) is a monoclonal antibody, and IgG antibodies are known to cross the placenta increasingly after the first trimester, with highest transfer in the third trimes. BENLYSTA is classified as Category C. First trimester: Based on animal studies, belimumab may cause fetal harm due to known immunomodulatory effects; limited human data. Second trimester: Potential for fetal B-cell dep. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.